How to improve ALCOA+ principles in pharmaceutical records

Pharmaceutical records are only useful when people can trust what they show.

A batch record, laboratory result, deviation record or electronic audit trail needs to provide reliable evidence of what happened, who performed the activity, when it happened and whether the information has remained complete and unchanged throughout its lifecycle.

ALCOA+ provides a practical framework for assessing that trustworthiness. The core ALCOA principles are attributable, legible, contemporaneous, original and accurate. The additional elements commonly include complete, consistent, enduring and available.

Improving ALCOA+ principles is therefore not a matter of adding a checklist to record review. It requires systems, procedures, training and behaviors that make good data integrity the normal way work is performed.

ALCOA+ should be built into the data lifecycle

Data integrity controls are strongest when they begin before a record is created.

FDA guidance describes data integrity as the completeness, consistency and accuracy of data throughout the CGMP data lifecycle. EMA guidance also emphasizes risk at each stage of the data lifecycle, including how original data and metadata are generated, stored, reviewed and retained.

That means organizations should assess the complete record lifecycle rather than focusing only on final approval.

The lifecycle can include

• Data creation.
• Recording.
• Review.
• Correction.
• Processing.
• Transfer.
• Approval.
• Storage.
• Retrieval.
• Archival.
• Retention.
• Disposition.

Each stage can strengthen or weaken ALCOA+ if the workflow is not designed carefully.

Organizations that need help connecting data-integrity expectations with documentation governance can use Bárd Global’s knowledge management and documentation consulting to examine records, workflows, ownership and source systems together.

Improve attributable records by strengthening identity and accountability

Attributable means the record can be linked to the person or system responsible for creating or changing it.

In paper records, that depends on controlled signatures, initials and clear responsibilities. In electronic environments, it depends on unique user access, audit trails and controls that prevent shared or anonymous accounts.

Attribution is weakened when a record shows what happened but not who performed the action.

Practical improvements include

• Use unique user accounts for electronic systems.
• Avoid shared logins for GxP activities.
• Define signature and initials controls for paper records.
• Make role responsibilities clear in procedures.
• Review audit trails where risk justifies it.
• Control administrator access appropriately.
• Document system-generated activities where attribution still needs explanation.

Good attribution supports accountability without relying on memory or informal knowledge.

Improve legibility by designing records for real use

Legibility is often treated as a handwriting issue, but it is wider than that.

A record should remain readable and understandable for the full retention period. Poor form design, cramped fields, unexplained abbreviations and low-quality scanned copies can all reduce legibility.

Electronic records also need to remain readable after system upgrades or migration.

Improve legibility by

• Providing enough space for required entries.
• Using clear field labels.
• Standardizing approved abbreviations.
• Avoiding ambiguous handwritten corrections.
• Checking the quality of certified copies or scans.
• Preserving readable electronic formats.
• Testing access to archived records after migration.

A record that technically exists but cannot be interpreted later does not provide reliable evidence.

Improve contemporaneous recording by removing workflow delays

Contemporaneous records are created when the activity is performed.

Problems appear when the process makes real-time recording inconvenient, such as when forms are stored away from the work area, systems are unavailable or staff are expected to reconstruct information later.

Improvement therefore requires more than telling people to write things down sooner.

Look for operational barriers such as

• Forms that are difficult to access during the task.
• Electronic systems with slow or unreliable access.
• Workflows that encourage notes on temporary paper.
• Data that is transcribed long after the source activity.
• Insufficient terminals or devices.
• Procedures that do not define when recording should occur.

Redesigning the workflow can be more effective than adding another reminder to the SOP.

Protect original records and their context

Original data is the first recording of the information, or an appropriately verified copy that preserves the content and meaning of the original.

In modern pharmaceutical systems, the original record may include metadata that is necessary to reconstruct the activity. EMA specifically highlights the importance of original data, its format and associated metadata when assessing completeness and accuracy.

That context matters when reviewing electronic data, audit trails and system-generated records.

Controls should address

• Where original data is created.
• Which system or medium is the official source.
• Whether metadata is retained.
• How certified copies are created.
• How data is transferred between systems.
• Whether temporary files exist before permanent storage.
• How migration preserves the complete record.

Organizations should avoid creating situations where a printed summary replaces important underlying electronic data.

Improve accuracy through prevention and review

Accuracy means records reflect the activity or measurement truthfully.

Review is important, but accuracy should not depend entirely on reviewers finding mistakes afterward.

Good process design reduces the opportunity for error before the record reaches review.

Accuracy controls can include

• Clear procedures.
• Validated calculations where appropriate.
• Controlled master data.
• System range or format checks.
• Independent verification for critical steps.
• Focused record review.
• Investigation of recurring corrections.
• Training on common data-entry risks.

Repeated corrections in the same field may indicate a design problem rather than individual carelessness.

Make records complete enough to reconstruct the activity

The ‘+’ in ALCOA+ expands attention beyond the original five principles.

Complete records contain the information needed to understand what actually occurred, including relevant repeats, reprocessing, reanalysis or failed attempts where these form part of the GxP record. FDA’s ALCOA+ framework describes completeness as information critical to recreating and understanding the event, including repeat or reanalysis data.

Selective recording can create a technically tidy record that does not represent the full activity.

Check completeness across

• Original observations.
• Repeat tests.
• Corrections.
• Attachments.
• Supporting calculations.
• Audit trails.
• Metadata.
• Exceptions and deviations.
• Associated forms or records.

The expected record set should be defined before review begins.

Improve consistency by controlling sequence, dates and terminology

Consistent data follows the expected sequence and uses coherent dating, time-stamping and terminology.

Inconsistency can make records difficult to reconstruct even when each individual entry appears reasonable.

Controlled terminology and synchronized system clocks can therefore become practical data-integrity controls.

Review consistency across

• Dates and times.
• Sequence of process steps.
• Document versions.
• Equipment identifiers.
• Sample identifiers.
• Product names.
• Status terminology.
• Linked records.

A controlled vocabulary can reduce interpretation problems where several teams or systems describe the same concept differently.

Make records enduring throughout the retention period

Enduring records remain intact throughout the period they are required.

Paper records can be damaged, lost or stored in unsuitable conditions. Electronic data can become inaccessible because hardware, software or file formats change.

Retention therefore needs to address both preservation and future readability.

For paper records, consider

• Approved storage areas.
• Protection from damage or loss.
• Controlled archive access.
• Retention schedules.
• Traceable retrieval and return.

For electronic records, consider

• Validated backup and restoration.
• Archive strategy.
• Format compatibility.
• System migration.
• Metadata preservation.
• Access to audit trails.
• Periodic checks that archived data remains retrievable.

Make records available, not merely retained

A record can be retained and still be difficult to access.

Availability means authorized users can retrieve the information when required throughout the defined retention period. FDA’s ALCOA+ framework similarly describes available data as information that can be accessed during the defined retention period.

Poor indexing, obsolete systems and unclear archive ownership can all create availability problems.

Improve availability with

• Clear indexing and metadata.
• Defined archive ownership.
• Documented retrieval procedures.
• Appropriate access controls.
• Tested backup restoration.
• Migration plans for retiring systems.
• Periodic archive retrieval checks.

Availability should be tested before an inspection, investigation or quality event makes retrieval urgent.

Good documentation practices make ALCOA+ easier

Many ALCOA+ failures begin with weak record design.

If a form does not provide the right fields, users create workarounds. If an SOP does not explain how corrections should be made, practices vary between teams. If required entries are unclear, reviewers interpret completeness differently.

Good documentation practices provide the operating structure around data integrity.

Review whether procedures clearly define

• Who records the information.
• When entries are made.
• How corrections are performed.
• How late entries are handled.
• What attachments form part of the record.
• How electronic and paper records interact.
• Who reviews the record.
• Where it is retained.

Where procedures or record templates need remediation, Bárd Global’s technical writing services can work with internal SMEs and quality teams to improve clarity while regulated approvals remain with the appropriate internal functions.

A hypothetical manufacturing record example

Consider a hypothetical manufacturing area where operators record equipment checks on a paper form.

Several fields are too small for the required information, so operators use arrows, margin notes and abbreviations. Reviewers regularly ask for clarification.

The problem may appear to be handwriting quality, but the underlying issue is record design.

Redesigning the form with clearer fields, approved abbreviations and defined correction instructions can improve legibility, completeness and accuracy without adding unnecessary review steps.

A hypothetical laboratory system example

Imagine a hypothetical laboratory where analysts generate electronic test data but also print summary results for review.

If reviewers rely only on the printout, they may not see metadata, repeat analyses or audit-trail information that forms part of the complete electronic record.

A stronger approach defines which electronic data and metadata need review based on risk and makes the official source clear.

This aligns record review with the actual data lifecycle rather than treating the printout as the entire record.

Use a risk-based approach to data integrity controls

Not every pharmaceutical record carries the same risk.

EMA guidance recommends considering data criticality and data risk throughout the lifecycle so that control measures are proportionate.

That allows organizations to focus stronger controls on data that has greater impact on product quality, patient safety or regulated decisions.

Risk assessment can consider

• How critical the data is to product quality.
• Whether the record supports batch disposition.
• Whether the data can be changed without detection.
• The degree of manual transcription.
• Complexity of the system.
• Number of users with modification rights.
• Whether audit trails are available.
• The consequences of incomplete or inaccurate records.

Risk-based controls should still meet applicable requirements. The purpose is to apply effort where it creates the most meaningful protection.

Culture and management controls matter

Data integrity cannot be sustained through technical controls alone.

If employees feel pressure to make records appear perfect, if errors are punished rather than investigated constructively or if unrealistic deadlines encourage shortcuts, record quality can suffer.

Management therefore has an important role in creating conditions where accurate documentation is expected and practical.

A stronger data-integrity culture supports

• Open reporting of mistakes.
• Clear escalation routes.
• Realistic workloads.
• Training based on actual record risks.
• Investigation of system and process causes.
• Appropriate segregation of duties.
• Management review of recurring integrity issues.

The objective is trustworthy data, not records that look flawless because problems were hidden.

AI and automation create new ALCOA+ questions

As pharmaceutical organizations introduce automation and AI-supported workflows, the principles remain relevant.

Organizations need to understand where data came from, what transformations occurred, what system generated an output and what human review remains necessary.

Automated content or data processing should not weaken traceability.

Questions to ask include

• Is the source data identifiable?
• Are transformations traceable?
• Are system changes logged?
• Can reviewers reconstruct how an output was produced?
• Are generated drafts clearly distinguished from approved records?
• Is human approval retained where judgment is required?

Bárd Global’s guidance on technical writing with AI explores why authoritative source content, governance and human validation remain important in AI-enabled documentation environments.

A practical ALCOA+ improvement program

Use this sequence

1. Map critical records. Identify the data and records that matter most to quality, safety and regulated decisions.
2. Map the lifecycle. Understand where each record is created, changed, reviewed, stored and retained.
3. Assess ALCOA+ risks. Look for gaps in attribution, contemporaneous recording, completeness, access and preservation.
4. Fix record design. Improve forms, systems and workflows that encourage poor documentation practices.
5. Clarify procedures. Define recording, correction, review, retention and retrieval expectations.
6. Strengthen system controls. Address access, audit trails, backup, metadata and administrator privileges where relevant.
7. Train around real risks. Use examples from the actual work rather than generic data-integrity slogans.
8. Review by risk. Focus review effort on critical data and points where errors or manipulation may be difficult to detect.
9. Monitor recurring issues. Use deviations, corrections and review observations to identify weak processes.
10. Verify effectiveness. Confirm that improvements make records more trustworthy and easier to reconstruct.

How Bárd Global supports pharmaceutical record quality

Bárd Global works with life sciences and other complex organizations where regulated information needs to remain accurate, usable and maintainable throughout its lifecycle.

Support can include SOP and form remediation, documentation audits, record-template improvement, terminology management, ownership clarification, knowledge governance and preparation of content for AI-supported retrieval.

Bárd works directly with internal SMEs and quality teams so documentation improvements remain connected to the approved process and the organization’s quality system.

With more than 25 years of experience, Bárd Global can support a focused remediation project or wider pharmaceutical documentation and knowledge operations.

If repeated record corrections, unclear forms or inconsistent documentation practices are creating data-integrity risk, talk to the Bárd Global team. We can help identify where documentation design and governance are contributing to the problem.

Frequently asked questions

What are ALCOA+ principles in pharmaceutical records?

ALCOA refers to attributable, legible, contemporaneous, original and accurate records.

The additional ‘+’ principles commonly include complete, consistent, enduring and available.

Together, they provide a practical framework for trustworthy pharmaceutical data and documentation.

Organizations should apply the principles throughout the data lifecycle rather than only during final review.

How can pharmaceutical companies improve ALCOA+ compliance?

Start by mapping critical records and identifying where data is created, changed, reviewed, stored and retained.

Improve weak forms, system access controls, metadata, audit trails, contemporaneous recording and archive processes according to risk.

Procedures and training should reflect the real workflow rather than generic rules.

Repeated errors should be investigated for process or system causes.

What is the difference between ALCOA and ALCOA+?

ALCOA covers attributable, legible, contemporaneous, original and accurate data.

ALCOA+ adds further lifecycle qualities such as completeness, consistency, endurance and availability.

The expanded framework emphasizes that trustworthy data must remain complete and accessible after it is first recorded.

Both concepts support the wider objective of pharmaceutical data integrity.

How should electronic records support ALCOA+?

Electronic systems should support unique attribution, secure access, reliable timestamps, preservation of original data and relevant metadata, appropriate audit trails, backup and long-term retrieval.

Controls should reflect the criticality and risk of the data.

Reviewers need access to the information required to reconstruct and assess the activity.

System design should also reduce opportunities for undocumented changes.

What are common ALCOA+ data integrity failures in pharma?

Common problems include shared logins, delayed recording, unofficial notes, incomplete metadata, unclear corrections, missing repeat data, inaccessible archives and reliance on printouts that do not represent the full electronic record.

Poorly designed forms and workflows can also drive repeated documentation errors.

Bárd Global can support document and record remediation, while internal quality functions retain responsibility for regulated decisions and approvals.

Build data integrity into the way records are created

Improving ALCOA+ principles is most effective when pharmaceutical companies look beyond final record review. Attribution, legibility, contemporaneous recording, originality and accuracy depend on how work is designed, while completeness, consistency, endurance and availability depend on how records are managed across their lifecycle.

Practical improvements to forms, systems, procedures, ownership and review can make pharmaceutical records easier to trust, reconstruct and use for quality decisions. If your organization needs support improving pharmaceutical records, GxP documentation or documentation governance, contact Bárd Global.